Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Phase IV Studies Need Greater Input From FDA, Industry Tells IoM Panel

Executive Summary

Drug manufacturers need more clarity from FDA regarding post-marketing studies, industry representatives told the Institute of Medicine's Committee on the Assessment of the U.S. Drug Safety System

You may also be interested in...



Advisory Committees In 2006: FDA Advisory Cmte. Reviews To Focus More On Lifecycle Of Drugs

Advisory Committees In 2006: FDA Advisory Cmte. Reviews To Focus More On Lifecycle Of Drugs

Drug Safety Issues Require “Courage” From Advisory Cmtes, Nissen Says

Advisory committees should be strengthened to better scrutinize safety data and improve advice given to FDA, Steve Nissen (Cleveland Clinic Foundation) said at the Jan. 17 meeting of the Institute of Medicine's Committee on the Assessment of the U.S. Drug Safety System

Related Content

UsernamePublicRestriction

Register

PS046813

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel